NeuroVive Pharmaceutical AB: Report From Extraordinary General Meeting

Published: Dec 13, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:

On 13 December, NeuroVive Pharmaceutical AB (publ) held an Extraordinary General Meeting (EGM), whose resolutions are summarized in what follows. All resolutions were reached with the requisite majority. Approval of the Board of Directors’ decision on a new share issue waiving shareholders’ preferential rights The Meeting approved the Board of Directors’ decision on the new issue of a maximum of 2,500,000 shares. Waiving shareholders’ preferential rights, a group of investors, selected in advance, that have notified the company of their interest in subscription, shall be entitled to subscribe for shares. If the share issue is fully subscribed, share capital would increase by SEK 125,000. SEK 14.00 shall be paid in cash for each share subscribed.

Help employers find you! Check out all the jobs and post your resume.

Back to news